Health News Releases

  • Today December 19
December 10, 2020 20:00
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual M
December 10, 2020 16:10
New Portal Allows Global Travellers to Book Mandatory Covid-19 Tests Around the World
Pure Health, the largest laboratory operator in the GCC, has launched a platform for travellers from any country to book Covid-19 pre-travel tests and get it done from anywhere in the world. The new p
December 10, 2020 15:55
Covetrus Completes Separation from Former Parent Company
Covetrus (Nasdaq: CVET), a global leader in animal-health technology and services, announced today that all 72 transitional services agreements with Henry Schein, Inc. (Nasdaq: HSIC), its former paren
December 10, 2020 10:57
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate i
December 08, 2020 16:59
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that China’s National Medical Products Administration (NMPA) has approved TAKHZYRO® (lanadelumab) subcutaneous inje
December 08, 2020 10:40
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic target
December 07, 2020 10:56
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin
December 07, 2020 10:49
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK
December 04, 2020 10:20
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery pla
December 02, 2020 17:05
PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina®
December 02, 2020 16:56
PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala
PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition
December 02, 2020 12:37
LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor
LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that U.S.
December 02, 2020 10:24
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administr
December 02, 2020 09:08
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport® (abobotulinumtoxinA)
December 01, 2020 14:10
Study Comparing Two Noninvasive Indicators of Fluid Responsiveness on Mechanically Ventilated Patients Finds Masimo PVi® Effective and Advantageous
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Ain-Shams Journal of Anesthesiology in which Dr. Diaaeldin Aboelnile and colleagues at Ain-Shams University in Cairo, Egy
December 01, 2020 11:08
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) f
November 26, 2020 17:10
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality
Regulatory News: Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron deficiency
November 26, 2020 15:45
Fitbit and JMDC Sign Agreement to Appoint JMDC as Exclusive Distributor of Fitbit Premium for Enterprise Customers in Japan
Fitbit (NYSE: FIT) today announced that JMDC (TOKYO: 4483) will be the exclusive distributor of Fitbit Premium, Fitbit’s paid membership service, for enterprise customers in Japan. JMDC, one of Jap
November 26, 2020 09:48
MEDIROM Healthcare Technologies Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering on NASDAQ
MEDIROM Healthcare Technologies Inc. (“MEDIROM”), the healthcare company which runs branded relaxation salons in Japan, today announced it has publicly filed a registration statement on Form F-1 with
November 25, 2020 11:25
Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans
Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat
November 24, 2020 14:50
Patient Safety Movement Foundation Launches New Commitment Model Supporting Mission to Achieve Zero Preventable Patient Deaths By 2030
Every year, more than 4.8 million patients lose their lives to preventable medical errors worldwide. The Patient Safety Movement Foundation (PSMF), a global non-profit, is committed to achieving zero
November 20, 2020 16:00
Walgreens Reinvents Nation’s Largest Health and Wellbeing-centered Loyalty Program with myWalgreens to Offer Customers Many More Benefits
Walgreens today announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offe
November 19, 2020 17:47
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia i
November 19, 2020 13:31
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2 diabetes and establis
November 18, 2020 19:10
PierianDx and Bench International Announce the Appointment of Mark McDonough as New CEO
PierianDx, the leading clinical genomics informatics company, and Bench International, a leading global executive search firm, jointly announce the appointment of Mark McDonough as Chief Executive Off
25 per page50 per page75 per page100 per page